At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
PPH VanEck Pharmaceutical ETF
Trading 11-02 10:13:36 EST
118.40
-0.93
-0.78%
High119.15Low118.40Vol63.55K
Open118.84D1 Closing119.33Amplitude0.63%
Mkt Cap1.09BTradable Cap1.09BTotal Shares9.24M
T/O7.55MT/O Rate0.69%Tradable Shares9.24M
P/B--ROE--EPS0.00
52wk High--52wk Low--P/E--
Dividend--Div.Yield--ROA--

Loading ...

3 Healthcare Stocks with ‘Strong Buy’ Analyst Ratings and ‘Perfect 10’ Smart Scores
TIPRANKS  ·  43 minutes ago
3 Healthcare Stocks with ‘Strong Buy’ Analyst Ratings and ‘Perfect 10’ Smart Scores
AbbVie signs global license agreement with Brise Pharmaceuticals in migraine
TIPRANKS  ·  22:12
AbbVie signs global license agreement with Brise Pharmaceuticals in migraine
Brise Pharmaceuticals Announces Global License Agreement with Abbvie to Advance the Next-Generation of Migraine Therapies
THOMSON REUTERS  ·  22:01
Brise Pharmaceuticals Announces Global License Agreement with Abbvie to Advance the Next-Generation of Migraine Therapies
Brise: Under Terms of Abbvie Deal, Potential Deal Value Could Reach up to US $757 Mln Plus Royalties on Future Sales
THOMSON REUTERS  ·  22:01
Brise: Under Terms of Abbvie Deal, Potential Deal Value Could Reach up to US $757 Mln Plus Royalties on Future Sales
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
Benzinga Earnings  ·  21:33
These Analysts Increase Their Forecasts On AbbVie After Strong Q3 Results
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
TIPRANKS  ·  21:16
Eli Lilly price target raised to $1,600 from $1,440 at Cantor Fitzgerald
Merck price target raised to $155 from $145 at Cantor Fitzgerald
TIPRANKS  ·  21:16
Merck price target raised to $155 from $145 at Cantor Fitzgerald
Street View: AbbVie's Immunology Strength Fuels Long-Term Growth Optimism
Reuters  ·  21:01
Street View: AbbVie's Immunology Strength Fuels Long-Term Growth Optimism
Merck to Present Phase 3 Data on Once-Weekly HIV Treatment at HIV Glasgow 2026
Reuters  ·  19:46
Merck to Present Phase 3 Data on Once-Weekly HIV Treatment at HIV Glasgow 2026
Cantor Fitzgerald Adjusts Price Target on Merck to $155 From $145
MT Newswires Live  ·  19:43
Cantor Fitzgerald Adjusts Price Target on Merck to $155 From $145
Abbvie : Bernstein Raises Target Price to $275 from $230
THOMSON REUTERS  ·  19:00
Abbvie : Bernstein Raises Target Price to $275 from $230
Novartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol Target
Reuters  ·  19:00
Novartis Heart Drug Failure Leaves Doctors Seeking Evidence for Genetic Cholesterol Target
BUZZ-US Stocks Weekly: Spooky
Reuters  ·  19:00
BUZZ-US Stocks Weekly: Spooky
Berenberg Adjusts Price Target on Eli Lilly and Company to $1,570 From $1,400
MT Newswires Live  ·  18:38
Berenberg Adjusts Price Target on Eli Lilly and Company to $1,570 From $1,400
Abbvie : Morgan Stanley Raises Target Price to $346 from $310
THOMSON REUTERS  ·  17:04
Abbvie : Morgan Stanley Raises Target Price to $346 from $310
Novartis Investors Might be Overlooking Risks
Dow Jones  ·  16:53
Novartis Investors Might be Overlooking Risks
Delhi High Court Restrains NPPA Action Against AstraZeneca
TIPRANKS  ·  14:34
Delhi High Court Restrains NPPA Action Against AstraZeneca
SKAN Reports Update on Federal Insider Investigation
TIPRANKS  ·  14:29
SKAN Reports Update on Federal Insider Investigation
Eli Lilly : Berenberg Raises Target Price to $1570 from $1400
THOMSON REUTERS  ·  13:59
Eli Lilly : Berenberg Raises Target Price to $1570 from $1400
Abbvie : Leerink Partners Raises Target Price to $325 from $279
THOMSON REUTERS  ·  11:45
Abbvie : Leerink Partners Raises Target Price to $325 from $279
No data available

Introduction

Company Name.
VanEck Pharmaceutical ETF
Affiliated Markets:
NASDAQ
Listing Date:
--
Main Business:
The fund normally invests at least 80% of its total assets in securities that comprise the fund's benchmark index. The index includes common stocks and depositary receipts of U.S. exchange-listed companies in the pharmaceutical industry. Such companies may include medium-capitalization companies and foreign companies that are listed on a U.S. exchange. It is non-diversified.
Issue price:
--